Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about QCLS, unsubscribe in one click. Privacy
QCLS holds $11M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations, an estimated runway of 12.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 18 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when QCLS files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QCLS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →